Literature DB >> 16007268

PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury.

Tomohisa Nagoshi1, Takashi Matsui, Takuma Aoyama, Annarosa Leri, Piero Anversa, Ling Li, Wataru Ogawa, Federica del Monte, Judith K Gwathmey, Luanda Grazette, Brian A Hemmings, Brian Hemmings, David A Kass, Hunter C Champion, Anthony Rosenzweig.   

Abstract

Acute activation of the serine-threonine kinase Akt is cardioprotective and reduces both infarction and dysfunction after ischemia/reperfusion injury (IRI). However, less is known about the chronic effects of Akt activation in the heart, and, paradoxically, Akt is activated in samples from patients with chronic heart failure. We generated Tg mice with cardiac-specific expression of either activated (myristoylated [myr]) or dominant-negative (dn) Akt and assessed their response to IRI in an ex vivo model. While dn-Akt hearts demonstrated a moderate reduction in functional recovery after IRI, no function was restored in any of the myr-Akt-Tg hearts. Moreover, infarcts were dramatically larger in myr-Akt-Tg hearts. Biochemical analyses demonstrated that chronic Akt activation induces feedback inhibition of PI3K activity through both proteasome-dependent degradation of insulin receptor substrate-1 (IRS-1) and inhibition of transcription of IRS-1 as well as that of IRS-2. To test the functional significance of these signaling changes, we performed in vivo cardiac gene transfer with constitutively active PI3K in myr-Akt-Tg mice. Restoration of PI3K rescued function and reduced injury after IRI. These data demonstrate that PI3K-dependent but Akt-independent effectors are required for full cardioprotection and suggest a mechanism by which chronic Akt activation can become maladaptive.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16007268      PMCID: PMC1172227          DOI: 10.1172/JCI23073

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  53 in total

1.  Prevention of fat-induced insulin resistance by salicylate.

Authors:  J K Kim; Y J Kim; J J Fillmore; Y Chen; I Moore; J Lee; M Yuan; Z W Li; M Karin; P Perret; S E Shoelson; G I Shulman
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

2.  Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure.

Authors:  S Haq; G Choukroun; H Lim; K M Tymitz; F del Monte; J Gwathmey; L Grazette; A Michael; R Hajjar; T Force; J D Molkentin
Journal:  Circulation       Date:  2001-02-06       Impact factor: 29.690

3.  Adenoviral gene transfer of activated phosphatidylinositol 3'-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro.

Authors:  T Matsui; L Li; Y Fukui; T F Franke; R J Hajjar; A Rosenzweig
Journal:  Circulation       Date:  1999-12-07       Impact factor: 29.690

4.  Insulin inhibits transcription of IRS-2 gene in rat liver through an insulin response element (IRE) that resembles IREs of other insulin-repressed genes.

Authors:  J Zhang; J Ou; Y Bashmakov; J D Horton; M S Brown; J L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

5.  Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo.

Authors:  T Matsui; J Tao; F del Monte; K H Lee; L Li; M Picard; T L Force; T F Franke; R J Hajjar; A Rosenzweig
Journal:  Circulation       Date:  2001-07-17       Impact factor: 29.690

6.  Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart.

Authors:  Y Fujio; T Nguyen; D Wencker; R N Kitsis; K Walsh
Journal:  Circulation       Date:  2000-02-15       Impact factor: 29.690

7.  A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1.

Authors:  T Haruta; T Uno; J Kawahara; A Takano; K Egawa; P M Sharma; J M Olefsky; M Kobayashi
Journal:  Mol Endocrinol       Date:  2000-06

8.  The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307).

Authors:  V Aguirre; T Uchida; L Yenush; R Davis; M F White
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

9.  Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C.

Authors:  H Tong; W Chen; C Steenbergen; E Murphy
Journal:  Circ Res       Date:  2000-08-18       Impact factor: 17.367

10.  Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1.

Authors:  K Yamashita; J Kajstura; D J Discher; B J Wasserlauf; N H Bishopric; P Anversa; K A Webster
Journal:  Circ Res       Date:  2001-03-30       Impact factor: 17.367

View more
  101 in total

1.  CITED4 induces physiologic hypertrophy and promotes functional recovery after ischemic injury.

Authors:  Vassilios J Bezzerides; Colin Platt; Carolin Lerchenmüller; Kaavya Paruchuri; Nul Loren Oh; Chunyang Xiao; Yunshan Cao; Nina Mann; Bruce M Spiegelman; Anthony Rosenzweig
Journal:  JCI Insight       Date:  2016-06-16

2.  C/EBPβ controls exercise-induced cardiac growth and protects against pathological cardiac remodeling.

Authors:  Pontus Boström; Nina Mann; Jun Wu; Pablo A Quintero; Eva R Plovie; Daniela Panáková; Rana K Gupta; Chunyang Xiao; Calum A MacRae; Anthony Rosenzweig; Bruce M Spiegelman
Journal:  Cell       Date:  2010-12-23       Impact factor: 41.582

3.  Artery/vein specification is governed by opposing phosphatidylinositol-3 kinase and MAP kinase/ERK signaling.

Authors:  Charles C Hong; Quinn P Peterson; Ji-Young Hong; Randall T Peterson
Journal:  Curr Biol       Date:  2006-07-11       Impact factor: 10.834

4.  Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.

Authors:  John Doukas; Wolfgang Wrasidlo; Glenn Noronha; Elena Dneprovskaia; Richard Fine; Sara Weis; John Hood; Anthony Demaria; Richard Soll; David Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-15       Impact factor: 11.205

5.  NADPH oxidase modulates myocardial Akt, ERK1/2 activation, and angiogenesis after hypoxia-reoxygenation.

Authors:  Jian-Xiong Chen; Heng Zeng; Qin-Hui Tuo; Heidi Yu; Barbara Meyrick; Judy L Aschner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-01-12       Impact factor: 4.733

6.  Constitutively active Akt inhibits trafficking of amyloid precursor protein and amyloid precursor protein metabolites through feedback inhibition of phosphoinositide 3-kinase.

Authors:  Diana W Shineman; Aleksandra S Dain; Minkyu L Kim; Virginia M-Y Lee
Journal:  Biochemistry       Date:  2009-05-05       Impact factor: 3.162

7.  Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet.

Authors:  Yolanda Jimenez-Gomez; Julie A Mattison; Kevin J Pearson; Alejandro Martin-Montalvo; Hector H Palacios; Alex M Sossong; Theresa M Ward; Caitlin M Younts; Kaitlyn Lewis; Joanne S Allard; Dan L Longo; Jonathan P Belman; Maria M Malagon; Placido Navas; Mitesh Sanghvi; Ruin Moaddel; Edward M Tilmont; Richard L Herbert; Christopher H Morrell; Josephine M Egan; Joseph A Baur; Luigi Ferrucci; Jonathan S Bogan; Michel Bernier; Rafael de Cabo
Journal:  Cell Metab       Date:  2013-10-01       Impact factor: 27.287

8.  Akt1 in the cardiovascular system: friend or foe?

Authors:  Brian T O'Neill; E Dale Abel
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

9.  AKT2 confers protection against aortic aneurysms and dissections.

Authors:  Ying H Shen; Lin Zhang; Pingping Ren; Mary T Nguyen; Sili Zou; Darrell Wu; Xing Li Wang; Joseph S Coselli; Scott A LeMaire
Journal:  Circ Res       Date:  2012-12-18       Impact factor: 17.367

10.  Cyclin D2 is a critical mediator of exercise-induced cardiac hypertrophy.

Authors:  Stephen W Luckey; Chris D Haines; John P Konhilas; Elizabeth D Luczak; Antke Messmer-Kratzsch; Leslie A Leinwand
Journal:  Exp Biol Med (Maywood)       Date:  2017-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.